IP Library Patent Application 11927480
Patent Application
App. No. 11/927,480

Nucleic Acid Detection Assays

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/927,480
Abstract

The present invention relates to novel methods of producing oligonucleotides. In particular, the present invention provides an efficient, safe, and automated process for the production of large quantities of oligonucleotides.

Claims (36)

1 . A high-throughput oligonucleotide production system comprising an oligonucleotide synthesizer component, wherein said oligonucleotide synthesizer component comprises at least 100 oligonucleotide synthesizers.

2 . An nucleic acid synthesis reagent delivery system comprising:

a. one or more reagent containers containing nucleic acid synthesis reagent;

b. a branched delivery component attached to said one or more reagent containers such that said nucleic acid synthesis reagent can pass from said reagent containers to said branched delivery component, wherein said branched delivery component comprises a plurality of branches;

c. a plurality of delivery lines, said plurality of delivery lines attached on one end to a branch of said branched delivery component and attached on a second end to a nucleic acid synthesizer.

3 . A nucleic acid assay container comprising a plurality of reaction sites, wherein two or more of said reaction sites contain one or more reagents configured to be mixed with a solution comprising a target nucleic acid to form a reaction mixture, wherein said one or more reagents comprises a reagent selected from the group consisting of a 5′ nuclease that lacks a polymerase activity, a FRET cassette, and a FRET probe, and wherein said reaction mixture comprises nucleic acids configured to form at least one invasive cleavage structure in the presence of said target nucleic acid.

4 . The nucleic acid assay container of claim 3 , wherein said one or more reagents comprise said 5′ nuclease, wherein said 5′ nuclease comprises a thermostable FEN-1 nuclease.

5 . The nucleic acid assay of claim 3 , wherein said one or more reagents comprise said 5′ nuclease, wherein said one or more reagents further comprise a probe.

6 . The nucleic acids assay of claim 5 , wherein said probe is a FRET probe.

7 . The nucleic acid assay container of claim 3 , wherein said one or more reagents comprise a plurality of FRET cassettes comprising distinct labels.

8 . The nucleic acid assay container of claim 3 , wherein said one or more reagents comprise a primer.

9 . The nucleic acid assay container of claim 3 , wherein said one or more reagents comprise a divalent cation.

10 . The nucleic acid assay container of claim 3 , wherein said one or more reagents are dried.

11 . The nucleic acid assay container of claim 3 , wherein said reaction sites comprise microwells.

12 . The nucleic acid assay container of claim 3 , wherein said reaction sites comprise reaction enclosures.

13 . The nucleic acid assay container of claim 12 , wherein said reaction enclosures are sealable.

14 . A method, comprising:

a) providing a nucleic acid assay container comprising a plurality of reaction sites, wherein two or more of said reaction sites contain one or more reagents configured to be mixed with a solution comprising a target nucleic acid to form a reaction mixture, wherein said reaction mixture comprises:

i) a 5′ nuclease that lacks polymerase activity, and

ii) assay nucleic acids configured to form an invasive cleavage structure in the presence of said target nucleic acid;

b) exposing at least said two or more reaction sites of said nucleic acid assay container to a solution suspected of containing a target nucleic acid under conditions wherein said assay nucleic acids form an invasive cleavage structure in the presence of said target nucleic acid;

c) determining the formation of an invasive cleavage structure in at least one reaction mixture.

15 . The method of claim 14 , wherein said one or more reagents comprises said 5′ nuclease.

16 . The method of claim 15 , wherein said 5′ nuclease comprises a FEN-1 nuclease.

17 . The method of claim 14 , wherein said one or more reagents comprises a probe.

18 . The method of claim 17 , wherein said probe is a FRET probe.

19 . The method of claim 14 , wherein said one or more reagents comprises a FRET cassette.

20 . The method of claim 14 , wherein said one or more reagents comprises a plurality FRET cassettes comprising distinct labels.

21 . The method of claim 14 , wherein said one or more reagents comprises a primer.

22 . The method of claim 14 , wherein said one or more reagents comprise a divalent cation.

23 . The method of claim 14 , wherein said one or more reagents are dried, and wherein said dried reagents are dissolved when mixed with said solution comprising a target nucleic acid.

24 . The method of claim 14 , wherein said target nucleic acid is amplified.

25 . The method of claim 24 , wherein said target nucleic acid is amplified by a polymerase chain reaction.

26 . The method of claim 14 , wherein said reaction sites comprise microwells.

27 . The method of claim 14 , wherein said reaction sites comprise reaction enclosures.

28 . The method of claim 14 , wherein said reaction enclosures are sealable.

Assignments (2)
TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS Recorded Aug 26, 2010
From: GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT
To: HOLOGIC, INC.; R2 TECHNOLOGY, INC.; SUROS SURGICAL SYSTEMS, INC.; BIOLUCENT, LLC; DIRECT RADIOGRAPHY CORP.; CYTYC SURGICAL PRODUCTS II LIMITED PARTNERSHIP; CYTYC SURGICAL PRODUCTS LIMITED PARTNERSHIP; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS III, INC.; CYTYC PRENATAL PRODUCTS CORP.; THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 024892/0001 →
SECURITY AGREEMENT Recorded Jul 29, 2008
From: THIRD WAVE TECHNOLOGIES, INC.
To: GOLDMAN SACHS CREDIT PARTNERS L.P., AS COLLATERAL AGENT
Reel/Frame 021301/0780 →